Standort in Deutschland, wo man günstige und qualitativ hochwertige Kamagra Ohne Rezept Lieferung in jedem Teil der Welt zu kaufen.

Wenn das Problem der Verringerung der Potenz berührt mich persönlich war ich schockiert, dass das passiert gerade mit mir viagra Übrigens jeder leisten und gibt eine sofortige Wirkung ohne Hausarbeiten Anwendungen.

130716_publikationen_evb

Publikationen aus der Klinik für Hämatologie, Onkologie und Palliativmedizin seit 2004

I. Originalarbeiten
Maschmeyer G, Böhme, A, Buchheidt D, Cornely OA, Fricke HJ, Karthaus M,
Lehrnbecher T, Link, Shah PM, Wilhelm M (2004): Diagnostik und Therapie von
Infektionen bei Patienten in der Hämatologie und Onkologie. Leitlinien der Sektion
Infektionen in der Hämatologie/Onkologie der Paul-Ehrlich-Gesellschaft e.V. Chemother
J 13: 134-141
Zaspel U, Denning DW, Lemke AJ, Greene R, Schürmann D, Maschmeyer G, Ruhnke
M, Herbrecht R, Ribaud P, Lortholary O, Zonderland H, Rabe KF, Röttgen R, Bittner R,
Neumann K, Oestmann JW (2004) Diagnosis of IPA in HIV: the role of the chest X-ray
and radiologist. Eur Radiol 14: 2030-2037
Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C, Ehninger G, Schaich M,
Mohr B, Niederwieser D, Krahl R, Pasold R, Döhner K, Ganser A, Döhner H, Heil G.
Individual patient data-based meta-analysis of patients aged 16 to 60 years with core
binding factor acute myeloid leukemia: a survey of the German Acute Myeloid
Leukemia Intergroup. J Clin Oncol. 2004 Sep 15;22(18):3741-50
Koenigsmann M, Knauf W, Herold M, Pasold R, Müller G, Eschenburg H, Kahl C,
Lakner V, Assmann M, Jentsch-Ullrich K, Mohren M, Bartsch R, Franke A. Fludarabine
and bendamustine in refractory and relapsed indolent lymphoma—a multicenter phase
I/II Trial of the east german society of hematology and oncology (OSHO). Leuk
Lymphoma. 2004 Sep;45(9):1821-7
Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B, Pott C,
Hartmann F, Rothmann F, Rohrberg R, Böck HP, Wandt H, Unterhalt M, Hiddemann
W; German Low-Grade Lymphoma Study Group. The addition of rituximab to a
combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly
increases the response rate and prolongs survival as compared with FCM alone in
patients with relapsed and refractory follicular and mantle cell lymphomas: results of a
prospective randomized study of the German Low-Grade Lymphoma Study Group.
Blood. 2004 Nov 15;104(10):3064-71.
Reich G, Cornely OA, Sandherr M, Kubin T, Krause S, Einsele H, Thiel E, Bellaire T,
Dörken B, Maschmeyer G (2005): Empirical antimicrobial monotherapy in patients after
high dose chemotherapy and autologous stem cell transplatation. A randomized,
multicentre trial. Br J Haematol 130: 265-270
Westermann J, Maschmeyer G, Lessen A, Dörken B, Pezzutto A (2005): CD52 is not a
promising immunotherapy target for most patients with multiple myeloma. Int J Hematol
82: 248-250
Giagounidis AA, Haase S, Germing U, Schlegelberger B, Wilkens L, Büsche G, Kreipe
HH, Wysk J, Grips KH, Grabenhorst U, Rothmann F, Lübbert M, Ganser A, Aivado M,
Heinsch M, Aul C. Treatment of myelodysplastic syndrome with isolated del(5q)
including bands q31-q33 with a combination of all-trans-retinoic acid and
tocopherolalpha: a phase II study. Ann Hematol. 2005 Jun;84(6):389-94.
Korfel A, Martus P, Nowrousian MR, Hossfeld DK, Kirchen H, Brücher J, Stelljes M,
Birkmann J, Peschel C, Pasold R, Fischer L, Jahnke K, Thiel E; German primary
central nervous system lymphoma Study Group (G-PCNSL-SG). Response to
chemotherapy and treating institution predict survival in primary central nervous system
lymphoma. Br J Haematol. 2005 Jan;128(2):177-83
Betts R, Glasmacher A, Maertens J, Maschmeyer G, Vazquez J, Teppler H, Taylor A,
Lupinacci R, Sable C, Kartsonis N (2006): Efficacy of caspofungin against invasive
Candida or invasive Aspergillus infections in neutropenic patients. Cancer 106: 466-473
Haas A, Maschmeyer G (2006): Das ökonomische Dilemma. Personenbezogene
Dienstleistungen unter den DRG-Bedingungen am Beispiel der Betreuung krebskranker
Patienten. Krankenhaus Umschau 05-2006: 412-416
Schiel X, Link H, Maschmeyer G, Glaß B, Cornely OA, Buchheidt D, Wilhelm M, Silling
G, Helmerking M, Hiddemann W, Ostermann H, Hentrich M for the Study Group of the
Paul Ehrlich-Society (2006): A prospective, randomized multicenter trial of the empirical
addition of antifungal therapy for febrile neutropenic cancer patients: Results of the Paul
Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infection 34:118-126
Maschmeyer G, Haas A (2006): Defining clinical failure for salvage studies. Med Mycol
44:S315-318
Maschmeyer G, Haas A (2006): Infektiöse Komplikationen als Folge der Behandlung
mit Nukleosidanaloga und monoklonalen Antikörpern. Dtsch Med Wschr 131:2414-2419
und TumorDiagn u Ther 27: 266-272
Haas A, Kahle W, Maschmeyer G (2006): Personalbedarfsanalyse für den ärztlichen
Dienst unter target costing Bedingungen. Krankenhaus Umschau 11/2006;11:1064-
1067
Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K,
Richter P, Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M,
Bittrich A, Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D; East German
Study Group of Hematology and Oncology (OSHO). Treatment of bendamustine and
prednisone in patients with newly diagnosed multiple myeloma results in superior
complete response rate, prolonged time to treatment failure and improved quality of life
compared to treatment with melphalan and prednisone--a randomized phase III study of
the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res
Clin Oncol. 2006 Apr;132(4):205-12
Glasmacher A, Cornely O, Ullmann AJ, Wedding U, Bodenstein H, Wandt H, Boewer C,
Pasold R, Wolf HH, Hänel M, Dölken G, Junghanss C, Andreesen R, Bertz H;
Itraconazole Research Group of Germany. An open-label randomized trial comparing
itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal
infections in patients with haematological malignancy and profound neutropenia. J
Antimicrob Chemother. 2006 Feb;57(2):317-25
Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, Siehl S,
Jäger U, Bergmann M, Stilgenbauer S, Schweighofer C, Wendtner CM, Döhner H,
Brittinger G, Emmerich B, Hallek M; German CLL Study Group. Fludarabine plus
cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with
chronic lymphocytic leukemia. Blood. 2006 Feb 1;107(3):885-91
Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P, Freund M, Ismer
B, Dachselt K, Boewer C, Schirmer V, Weniger J, Pasold R, Winkelmann C,
Klinkenstein C, Schulze M, Arzberger H, Bremer K, Hahnfeld S, Schwarzer A, Müller C,
Müller C; for the East German Study Group Hematology and Oncology (OSHO).
Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine
and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell
lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin
Oncol. 2006 Feb;132(2):105-12
Haas A, Maschmeyer G (2006): Die elektronische Gesundheitskarte in Deutschland.
Brandenburgisches Ärzteblatt 11-2006: 291-293
Haas A, Lobeck H, Hummel M, Maschmeyer G (2006): Anhaltende Remission nach
Immuntherapie bei zuvor refraktärem peripheren T-Non-Hodgkin-Lymphom. Dtsch Med
Wschr 131: 2386-2389
Montemurro M, Kiefer T, Schüler F, Al-Ali HK, Wolf HH, Herbst R, Haas A, Helke K,
Theilig A, Lotze C, Hirt C, Niederwieser D, Schwenke M, Krüger WH, Dölken G.
Primary central nervous system lymphoma treated with high-dose methotrexate, high-
dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted
wholebrain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe
Hamato- Onkologie OSHO-53 phase II study. Ann Oncol. 2007 Apr;18(4):665-71
Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berde WE,
Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick
O; German Testicular Cancer Study Group. Single versus sequential high-dose
chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective
randomized multicenter trial of the German Testicular Cancer Study Group. J Clin
Oncol. 2007 Jul 1;25(19):2778-84
Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, Dölken G, Naumann R,
Knauf W, Freund M, Rohrberg R, Höffken K, Franke A, Ittel T, Kettner E, Haak U, Mey
U, Klinkenstein C, Assmann M, von Grünhagen U; East German Study Group,
Hematology and Oncology Study. Rituximab added to first-line mitoxantrone,
chlorambucil, and prednisolone chemotherapy followed by interferon maintenance
prolongs survival in patients with advanced follicular lymphoma: an East German Study
Group Hematology and Oncology Study. J Clin Oncol. 2007 May 20;25(15):1986-92
Maschmeyer G, Haas A, Dickerhoff R, Kleber FX (2007): Pulmonale Hypertonie bei
Sichelzellkrankheiten. Epidemiologie, Pathogenese, Diagnostik, Therapie. Dtsch Med
Wschr 132: 103-107
De Pauw B, Walsh TJ, Donnelly JP, Stevens D, Edwards JE, Calandra T, Pappas P,
Maertens J, Lortholary O, Kauffman CA, Denning DW, Patterson TF, Maschmeyer G,
Bille J, Dismukes WE, Herbrecht R, Hope WW, Kibbler CC, Kullberg BJ, Marr KA,
Perfect JR, Restrepo A, Ruhnke M, Segal BH, Sobel J, Sorrell TC, Viscoli C, Wingard
JR, Zaoutis T, Bennett JE (2008): Revised definitions of the EORTC/MSG consensus
group for invasive fungal diseases. Clin Infect Dis 2008;46:1813-21
Rothmann F, Maschmeyer G (2008): Systemische AL-Amyloidose: neue Daten zur
Therapie mit Thalidomid, Cyclophosphamid, Dexamethason und Lenalidomid.
Arzneimittelbrief 41: 60-61
Cornely OA, Böhme A, Reichert D, Reuter S, Maschmeyer G, Maertens J, Buchheidt
D, Paluszewska M, Arenz D, Bethe U, Effelsberg J, Lövenich H, Sieniawski M, Haas A,
Einsele H, Eimermacher H, Martino R, Silling G, Hahn M, Wacker S, Ullmann AJ,
Karthaus M (2008) Secondary prophylaxis after invasive pulmonary fungal infections in
acute myelogenous leukemia patients from 25 European cancer centers. J Antimicrob
Chemother 61:939-46
Pönisch W, Rozanski M, Goldschmidt H, Hoffmann FA, Boldt T, Schwarzer A, Ritter U,
Rohrberg R, Schwalbe E, Uhlig J, Zehrfeld T, Schirmer V, Haas A, Kreibich U,
Niederwieser D; East German Study Group of Haematology and Oncology (OSHO).
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed
multiple myeloma after autologous stem-cell transplantation or conventional
chemotherapy: results of a Phase I clinical trial. Br J Haematol. 2008 Oct;143(2):191-
200
Kiefer T, Krüger WH, Montemurro M, Schüler F, Hirt C, Pasold R, Niederwieser D,
Schwenke M, Dölken G. Mobilization of hemopoietic stem cells with high-dose
methotrexate plus granulocyte-colony-stimulating factor in patients with primary central
nervous system lymphoma. Transfusion. 2008 Dec;48(12):2624-8
Hirt C, Schüler F, Kiefer T, Schwenke C, Haas A, Niederwieser D, Neser S, Assmann
M, Srock S, Rohrberg R, Dachselt K, Leithäuser M, Rabkin CS, Herold M, Dölken G.
Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus
rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced
stage follicular lymphoma patients. Br J Haematol. 2008 May;141(5):631-40
Wolf HH, Leithäuser M, Maschmeyer G, Salwender H, Klein U, Chaberny I, Weissinger
F, Buchheidt D, Ruhnke M, Egerer G, Fätkenheuer G, Mousset S (2008): Central
venous catheter-related infections in hematology and oncology: Guidelines of the
Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and
Oncology (DGHO). Ann Hematol 87:863-876
Maschmeyer G, Neuburger S, Fritz L, Böhme A, Penack O, Schwerdtfeger R,
Buchheidt D, Ludwig WD (2009): A prospective, randomised study on the use of well-
fitting masks for prevention of invasive aspergillosis in high-risk patients. Ann Oncol
20:1560-1564
Maschmeyer G, Beinert T, Buchheidt D, Cornely OA, Einsele H, Heinz W, Heussel CP,
Kahl C, Kiehl M, Lorenz J, Hof H, Mattiuzzi G (2009): Diagnosis and antimicrobial
therapy of pulmonary infiltrates in febrile neutropenic patients. 2008 updated guidelines
of the Infectious Diseases Working Party of the German Society of Hematology and
Oncology. Eur J Cancer 45:2462-2472
Lengfelder E, Haferlach C, Saussele S, Haferlach T, Schultheis B, Schnittger S, Ludwig
WD, Staib P, Aul C, Grüneisen A, Kern W, Reichle A, Serve H, Berdel WE, Braess J,
Spiekermann K, Wörmann B, Sauerland MC, Heinecke A, Hiddemann W, Hehlmann R,
Büchner T; German AML Cooperative Group (2009): High-dose ara-C in the
treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the
German AMLCG. Leukemia 23: 2248-2258
Cornely OA, Böhme A, Buchheidt D, Einsele H, Heinz W, Karthaus M, Krause SW,
Krüger W, Maschmeyer G, Penack O, Ritter J, Ruhnke M, Sandherr M, Sieniawski M,
Vehreschild JJ, Wolf HH, Ullmann AJ (2009): Primary prophylaxis of invasive fungal
infections in patients with hematological malignancies. Recommendations of the
Infectious Diseases Working Party of the German Society of Hematology and
Oncology. Haematologica 94:113-22
Böhme A, Ruhnke M, Buchheidt D, Cornely OA, Einsele H, Enzensberger R, Hebart H,
Heinz W, Junghanss C, Karthaus M, Krüger W, Krug U, KubinT, Penack O, Reichert D,
Reuter S, Silling G, Südhoff T, Ullmann AJ, Maschmeyer G (2009): Treatment of
invasive fungal infections in cancer patients – Recommendations of the Infectious
Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology
(DGHO). Ann Hematol 88:97-110
Büchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Müller-Tidow C, Braess
J, Spiekermann K, Kienast J, Staib P, Grüneisen A, Kern W, Reichle A, Maschmeyer
G
, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wörmann B, Hiddemann W (2009):
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a
study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 27: 61-
69
Vehreschild JJ, Sieniawski M, Reuter S, Arenz D, Reichert D, Maertens J, Böhme A,
Martino R, Maschmeyer G, Rüping MJGT, Ullmann AJ, Cornely OA (2009): Efficacy of
caspofungin and itraconazole as secondary antifungal prophylaxis: an analysis of data from a multinational case registry. Int J Antimicrob Agents 34: 446-450 Basara N, Schulze A, Wedding U, Mohren M, Gerhardt A, Junghanss C, Peter N,
Dölken G, Becker C, Heyn S, Kliem C, Lange T, Krahl R, Pönisch W, Fricke HJ, Sayer
HG, Al-Ali H, Kamprad F, Niederwieser D; East German Study Group Hematology and
Oncology (OSHO) (2009): Early related or unrelated haematopoietic cell transplantation
results in higher overall survival and leukaemia-free survival compared with
conventional chemotherapy in high-risk acute myeloid leukaemia patients in first
complete remission. Leukemia. 23:635-40.
Tintelnot K, Just-Nübling G, Horré R, Graf B, Sobottka I, Seibold M, Haas A, Kaben U,
De Hoog GS (2009): A review of German Scedosporium prolificans cases from 1993 to
2007. Med Mycol. 47:351-8
Rüping MJ, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flörl C, Beisel C, Herbrecht R, Roth
Y, Silling G, Ullmann AJ, Borchert K, Egerer G, Maertens J, Maschmeyer G, Simon A,
Wattad M, Fischer G, Vehreschild JJ, Cornely OA (2010): Forty-one recent cases of
invasive zygomycosis from a global clinical registry. J Antimicrob Chemother 65: 296-
302
Krug U, Rölling C, Koschmieder A, Heincke A, Sauerland MC, Schaich M, Thiede C,
Kramer M, Braess J, Spiekermann K, Haferlach T, Haferlach C, Koschmieder S, Rohde
C, Serve H, Wörmann B, Hiddemann W, Ehninger G, Berdel WE, Büchner T, Müller-
Tidow C, German Acute Myeloid Leukemia Cooperative Group and Study Alliance
Leukemia Investigators (2010): Complete remission and early death after intensive
chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-
based application for prediction of outcomes. Lancet 376: 2000-2008
Thuss-Patience PC, Kretzschmar A, Dogan Y, Rothmann F, Blau I, Schwaner I,
Breithaupt K, Bichev D, Grothoff M, Grieser C, Reichardt P. Docetaxel and capecitabine
for advanced gastric cancer: investigating dose-dependent efficacy in two patient
cohorts. Br J Cancer. 2011 Aug 9;105(4):505-12
Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M,
Kranzhöfer N, Rohrberg R, Söling U, Burkhard O, Westermann A, Goede V,
Schweighofer CD, Fischer K, Fink AM, Wendtner CM, Brittinger G, Döhner H,
Emmerich B, Hallek M; German CLL Study Group (GCLLSG) (2009): First-line
therapy with fludarabine compared with chlorambucil does not result in a major benefit
for elderly patients with advanced chronic lymphocytic leukemia. Blood 114:3382-3391
Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, Bergmann M,
Stilgenbauer S, Hopfinger G, Ritgen M, Bahlo J, Busch R, Hallek M; German CLL
Study Group
(GCLLSG) (2011): Limited clinical relevance of imaging techniques in the
follow-up of patients with advanced chronic lymphocytic leukemia: results of a
metaanalysis Blood 117:1817-1821
Al-Ali H, Jaekel N, Junghanss C, Maschmeyer G, Krahl R, Cross M, Hoppe G,
Niederwieser D (2012): Azacitidine in patients with acute myeloid leukemia medically
unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma
53: 110-117
Ruhnke M, Böhme A, Buchheidt D, Cornely O, Donhuijsen K, Einsele H, Enzensberger
R, Hebart H, Heussel CP, Horger M, Hof H, Karthaus M, Krüger W, Maschmeyer G,
Penack O, Ritter J, Schwartz S (2012): Diagnosis of invasive fungal infections in
haematology and oncology - Guidelines from the Infectious Diseases Working Party in
Haematology and Oncology of the German Society for Haematology and Oncology
(AGIHO). Ann Oncol 23: 823-833
Vehreschild MLGT, Meissner A, Cornely OA, Maschmeyer G, Neumann S, von
Lilienfeld-Toal M, Karthaus M, Wattad M, Staib P, Hellmich M, Christ H, Vehreschild JJ
(2011): Clinically defined chemotherapy-associated bowel syndrome predicts severe
complications and death in cancer patients. Haematologica 96: 1855-1860
Kiefer T, Hirt C, Späth C, Schüler F, Al-Ali HK, Wolf HH, Herbst R, Maschmeyer G,
Helke K, Kessler C, Niederwieser D, Busemann C, Schroeder H, Vogelgesang S,
Kirsch M, Montemurro M, Kröger WH, Dölken G (2012): Long-term follow-up of high-
dose chemotherapy with autologous stem-cell transplantation and response-adapted
whole-brain radiotherapy for newly diagnosed primary CNS lymphoma: results of the
multicenter Ostdeutsche Studiengruppe Hamatologie und Onkologie OSHO-53 phase II
study. Ann Oncol 23: 1809-1812
Reinwald M, Spiess B, Heinz W, Vehreschild J, Lass-Floerl C, Kiehl M, Schultheis B,
Krause S, Wolff H, Bertz H, Maschmeyer G, Hofmann W, Buchheidt D (2012):
Diagnosing pulmonary aspergillosis in patients with hematological malignancies: A
multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan
ELISA in bronchoalveolar lavage samples. Eur J Haematol 89: 120-127
Gökbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, Fietkau R, Freund
M, Ganser A, Ludwig WD, Maschmeyer G, Rieder R, Schwartz S, Serve H, Thiel E,
Brüggemann M, Hoelzer D (2012): Adults with acute lymphoblastic leukemia and
molecular failure display a poor prognosis and are candidates for SCT and targeted
therapies. Blood 120: 1868-1876
Büchner T, Berdel WE, Krug UO, Haferlach C, Schnittger S, Müller-Tidow C, Braess J,
Spiekermann K, Stelljes M, Mesters R, Silling G, Grüneisen A, Reichle A, Ludwig WD,
Maschmeyer G, Balleisen L, Giagounidis A, Rasche H, Hehlmann R, Lengfelder E,
Thiel E, Sauerland MC, Heinecke A, Woermann BJ, Hiddemann W (2012): Long-term
Results in Acute Myeloid Leukemia (AML): Prospective study to quantify the influence
of age, treatment variables and risk factors. Blood (eingereicht)
Dreger P, Döhner H, McClanahan F, Busch R, Ritgen M, Greinix H, Fink AM, Knauf W,
Stadler M, Pfreundschuh M, Dührsen U, Brittinger G, Hensel M, Schetelig J, Winkler D,
Bühler A, Kneba M, Schmitz N, Hallek M, Stilgenbauer S; German CLL Study Group
(2012): Early autologous stem cell transplantation for chronic lymphocytic leukemia:
long-term follow-up of the German CLL Study Group CLL3 trial. Blood 119: 4851-4859
Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM,
Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann
W, Bohlander SK, Spiekermann K; AMLCG Study Group (2012): Monoallelic CEBPA
mutations in normal karyotype acute myeloid leukemia: independent favorable
prognostic factor within NPM1 mutated patients. Ann Hematol 91: 1051-1063
Oertel K, Spiegel K, Schmalenberg H, Dietz A, Maschmeyer G, Kuhnt T, Südhoff H ,
Wendt TG, Guntinas-Lichius O (2012): Phase I trial of split-dose induction docetaxel,
cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined
with postoperative radiotherapy in patients with locally advanced oral and
oropharyngeal squamous cell cancer (TISOC-1). BMC Cancer 12: 483
Maschmeyer G, Heinz WJ, Hertenstein B, Horst HA, Requadt C, Wagner T, Cornely
OA, Löffler J, Ruhnke M on behalf of the IDEA study investigators (2013): Immediate
versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile
neutropenia: A randomised, double-blind, placebo-controlled, multicentre study. Eur J
Clin Microbiol Infect Dis 32: 679-89
Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C,
Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H,
Strauch M, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2013): Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment in patients with indolent and mantle cell lymphomas: results of a prospective, open-label, multi-centre, randomised, phase 3, non-inferiority trial. Lancet 381: 1203-10 Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A,
Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A,
Pfreundschuh M, Loeffler M, Glass B; German High-Grade Lymphoma Study Group
(DSHNHL) (2012): Conventional chemotherapy (CHOEP-14) with rituximab or high-
dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with
aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-
1). Lancet Oncol 13: 1250-1259
Vehreschild MJ, Vehreschild JJ, Hübel K, Hentrich M, Schmidt-Hieber M, Christopeit M,
Maschmeyer G, Schalk E, Cornely OA, Neumann S (2013): Diagnosis and
management of gastrointestinal complications in adult cancer patients: evidence-based
guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of
Hematology and Oncology (DGHO). Ann Oncol 24: 1189-202
Neumann S, Krause SW, Maschmeyer G, Schiel X, von Lilienfeld-Toal M (2013):
Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in
patients with hematological malignancies and solid tumors. Guidelines of the Infectious
Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology
(DGHO). Ann Hematol 2013; 92:433-442
Wongso D, Fuchs M, Pluetschow A, Klimm B, Sasse S, Hertenstein B, Maschmeyer G,
Vieler T, Dührsen U, Lindemann W, Aulitzky W, Diehl V, Borchmann P, Engert A
(2013): Treatment-related mortality in patients with advanced-stage Hodgkin
Lymphoma: an analysis of the German Hodgkin Study Group (GHSG). J Clin Oncol, e-
pub 24 June 2013
Cross M, Bach E, Tran T, Krahl R. Jaekel N, Niederwieser D, Junghanß C,
Maschmeyer G,
Al-Ali HK, (2013): Pre-treatment LINE-1 methylation levels, not early
hypomethylation under treatment, predict haematological response to azacitidine in
elderly patients with acute myeloid leukaemia. OncoTargets and Therapy, e-pub 19
June 2013

II. Übersichtsartikel und Buchbeiträge

1. Maschmeyer G (2004): Infektionen bei malignen Erkrankungen. In: Hiddemann W, Bartram
CR, Huber H (Hrsg.): Die Onkologie. 1. Aufl., Springer-Verlag Heidelberg-Berlin, S. 781-798 2. Maschmeyer G (2004): Infektionen bei Abwehrschwäche (ohne AIDS) beim Erwachsenen.
In: Suttorp N, Mielke M, Stück B, Kiehl W (Hrsg.): Infektionskrankheiten. Georg Thieme Verlag Stuttgart, S. 559-571 3. Maschmeyer G, Göbel UB (2004): Stenotrophomonas maltophilia and Burkholderia
cepacia. In: Mandell GL, Bennett JE, Dolin R: Principles and Practice of Infectious Diseases, 6th edition, Elsevier Science (USA), Philadelphia, S. 2615-2621 4. Maschmeyer G, Ruhnke M (2004): Update on antifungal treatment of invasive Candida and
Aspergillus infections. Mycoses 47: 263-276 5. Maschmeyer G (2004): Cefepim in der empirischen Initialtherapie bei febrilen
neutropenischen Patienten mit malignen Erkrankungen. Chemother J 13: 174-180 6. Büchner T, Hiddemann W, Berdel WE, Wörmann B, Löffler H, Schoch C, Haferlach T, Ludwig WD, Maschmeyer G, Lengfelder E, Staib P, Andreesen R, Balleisen L, Haase D,
Eimermacher H, Schumacher A, Aul C, Rasche H, Uhlig J, Grüneisen A, Reis HE, Hartlapp
J, Hirschmann WD, Weh HJ, Pielken HJ, Gassmann W, Sauerland MC, Heinecke A (2004):
Acute myeloid leukemia (AML): the role of intensive induction chemotherapy. Int J Hematol
Oncol Bone Marrow Transplant 1: 1-5
7. Büchner T, Hiddemann W, Berdel WE, Wörmann B, Löffler H, Schoch C, Haferlach T, Ludwig WD, Maschmeyer G, Lengfelder E, Staib P, Andreesen R, Balleisen L, Haase D,
Eimermacher H, Schumacher A, Aul C, Rasche H, Uhlig J, Grüneisen A, Reis HE, Hartlapp
J, Hirschmann WD, Weh HJ, Pielken HJ, Gassmann W, Sauerland MC, Heinecke A (2004):
Acute myeloid leukemia (AML): the role of maintenance chemotherapy. Int J Hematol Oncol
Bone Marrow Transplant 1: 6-11
8. Maschmeyer G (2004): Professionelles Infektionsmanagement in der Hämatologie/
Onkologie trägt Früchte. Onkologie heute 06/2004: 4-5 9. Maschmeyer G (2005): Management of vancomycin-resistant enterococci – a Paradigm.
10. Maschmeyer G (2005) Pathogenic Fungi: Host interactions and emerging strategies for
control (book review). Expert Rev Anti Infect Ther 3: 7-8 11. Maschmeyer G, Glasmacher A (2005): Pharmacological properties and clinical efficacy of a
recently licensed systemic antifungal, caspofungin. Mycoses 48: 227-234 12. Maschmeyer G, Haas A, Böhme A (2005): Aktuelle Therapie invasiver Mykosen in der
Hämatologie und Onkologie. Dtsch Med Wschr 130: 1381-1384 13. Link H, Maschmeyer G (2005): Therapie und Prophylaxe von Infektionen bei Neutropenie.
In: Schmoll HJ, Höffken K, Possinger K (Hrsg.): Kompendium Internistische Onkologie, 4. Aufl., Springer-Verlag Berlin Heidelberg New York, S. 2088-2131 14. Maschmeyer G, Schwarz M (2005): Onkologische Notfälle (R Gucalp, J Dutcher). In: Dietel
M, Suttorp N, Zeitz M (Hrsg.): Harrisons Innere Medizin, 16. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 617-625 15. Schwarz M, Maschmeyer G (2005): Spätfolgen von Krebserkrankungen und ihrer
Behandlung (MC Perry, DL Longo). In: Dietel M, Suttorp N, Zeitz M (Hrsg.): Harrisons Innere Medizin, 16. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 626-628 16. Maschmeyer G (2005): Erkrankungen der Plasmazellen (DL Longo, KC Anderson). In:
Dietel M, Suttorp N, Zeitz M (Hrsg.): Harrisons Innere Medizin, 16. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 703-709 17. Maschmeyer G (2005): Management von Systemmykosen. Symposium Medical
18. Neuburger S, Maschmeyer G (2006): Update on management of infections in cancer and
stem cell transplant patients. Ann Hematol 85: 345-356 19. Maschmeyer G (2006): The changing epidemiology of invasive fungal infections: new
20. Genvresse I, Maschmeyer G (2006): Chickenpox and zoster in marrow transplant
recipients. In: Doerr DW, Gross G (Hrsg.): Herpes Zoster. Monographs in Virology, Karger-Verlag, Basel, 2006, Vol. 26, S. 107-116 21. Maschmeyer G, Haas A (2006): Voriconazole: a broad spectrum triazole for the treatment
of serious and invasive fungal infections. Future Microbiology 1:365-385 22. Maschmeyer G (2006): Infektionsprophylaxe bei Tumorpatienten. 30. Forumband
„Fortschritt und Fortbildung in der Medizin“: S. 227-233, Bundesärztekammer 2006 23. Maschmeyer G (2006): Behandlung invasiver Pilzinfektionen. Medizin Forum Aktuell Nr.
24. Maschmeyer G, Haas A (2006): Infektionen bei immunkompromittierten Patienten. In: Van
Aken, Reinhart, Zimpfer, Welte (Hrsg.): Intensivmedizin. Georg Thieme Verlag Stuttgart, S. 792-799 25. Maschmeyer G, Haas A (2006): Invasive Pilzinfektionen. In: Van Aken, Reinhart, Zimpfer,
Welte (Hrsg.): Intensivmedizin. Georg Thieme Verlag Stuttgart, S. 786-791 26. Maschmeyer G, Haas A, Cornely OA (2007): Invasive Aspergillosis: Epidemiology,
Diagnosis and Management in Immunocompromised Patients. Drugs 2007; 67:1567-601 27. Peters U, Maschmeyer G (2007): Fieber und Infektionen. In: Aulbert/Nauck/Radbruch
(Hrsg.) Lehrbuch der Palliativmedizin, 2. Auflage. Schattauer Verlag Stuttgart, S. 419-428 28. Sandherr M, Maschmeyer G (2007): Infektionen in der Onkologie. Best Practice Onkologie
29. Maschmeyer G, Haas A (2007): Die Behandlung des Myeloms – heute. Arzneiverordnung
30. Maschmeyer G, Haas A (2007): Therapie der febrilen Neutropenie. OnkoLogisch 2/2007:
31. Maschmeyer G, Haas A (2008): The epidemiology and treatment of infections in cancer
patients. Int J Antimicrob Agents 31: 193–197 32. Neuburger S, Maschmeyer G (2007): Changing epidemiology and challenges of fungal
infections in bone marrow transplantation. European Infectious Diseases Touch Briefings 2007: 61-62 33. Haas A, Maschmeyer G, Grebner S (2007): Möglichkeiten und Grenzen standardisierter
Prozessorganisation im Krankenhaus. Gesundheits- und Sozialpolitik 11-12/2007: S. 48-55 34. Maschmeyer G (2008): Therapie von Bronchialkarzinomen. Pharmazeutische Zeitung
35. Haas A, Maschmeyer G (2008): Antibiotikatherapie in der Schwangerschaft. Dtsch Med
36. Maschmeyer G (2008): Invasive aspergillosis in severely immunosuppressed patients –
Significant progress, but many unresolved problems. Transpl Infect Dis 2008;10:151-155 37. Maschmeyer G (2008): Erkrankungen der Plasmazellen (NC Munshi, DL Longo, KC
Anderson). In: Dietel M, Suttorp N, Zeitz M (Hrsg.): Harrisons Innere Medizin, 17. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 874-882 38. Maschmeyer G, Haas A (2008): Onkologische Notfälle (R Gucalp, J Dutcher). In: Dietel M,
Suttorp N, Zeitz M (Hrsg.): Harrisons Innere Medizin, 17. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 2130-2141 39. Maschmeyer G, Rothmann F (2008): Spätfolgen von Krebserkrankungen und ihrer
Behandlung (MC Perry, DL Longo). In: Dietel M, Suttorp N, Zeitz M (Hrsg.): Harrisons Innere Medizin, 17. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, e91-95 40. Maschmeyer G (2009): Pilzinfektionen. In: Arzneimittelkommission der Deutschen
Ärzteschaft (Hrsg.): Arzneiverordnungen, 22. Aufl., Medizinische Medien Informations-Verlag Berlin 41. Maschmeyer G (2008): Thalidomid-Abkömmling Lenalidomid wirksam bei rezidiviertem
oder refraktärem multiplen Myelom. Arzneiverordnung in der Praxis 35: 96-97 42. Maschmeyer G (2009): Micafungin und Anidulafungin – neue Optionen zur Behandlung
von Candidämie und invasiven Mykosen? Arzneiverordnung in der Praxis 36: 18-19 43. Sandherr M, Maschmeyer G (2008): Antimikrobielle Therapie bei Patienten mit soliden
Tumoren und hämatologischen Neoplasien. Im Focus Onkologie 10: 54-60 44. Maschmeyer G, Sandherr M (2009): Infektionen in der Hämatologie und Onkologie.
45. Maschmeyer G (2009): Prevention of mould infections. J Antimicrob Chemother 63 Suppl
46. Breywisch F, Maschmeyer G (2009): Allogene und autologe Stammzelltransplantation –
eine Übersicht. Brandenburgisches Ärzteblatt 19: 16-30 47. Maschmeyer G, Calandra T, Singh N, Wiley J, Perfect J (2009): Invasive mould infections:
a multi-disciplinary update. Med Mycol 2009;47: 571-583 48. Maschmeyer G, Haas A (2008): Systemische Mykosen. In: Nowrousian MR (Hrsg.):
Supportive Therapie in der Onkologie (2. Aufl.). Zuckschwerdt Verlag München Wien New York, S. 209-217 49. Haas A, Maschmeyer G (2008): Onkologische Notfälle. In: Nowrousian MR (Hrsg.):
Supportive Therapie in der Onkologie (2. Aufl.). Zuckschwerdt Verlag München Wien New York, S. 237-255 50. Maschmeyer G (2009): Infektionen bei malignen Erkrankungen. In: Hiddemann W, Bartram
CR, Huber H (Hrsg.): Die Onkologie. 2. Aufl., Springer-Verlag Heidelberg-Berlin, S. 768-781 51. Dickerhoff R, von Rücker A, Maschmeyer G, Heimpel H (2009): Probleme erwachsener
Sichelzellpatienten in Deutschland. Dtsch Med Wochenschr 134: 1179-1184 52. Maschmeyer G, Patterson TF (2009): New immunosuppressive agents and risk for
invasive fungal infection. Curr Infect Dis Rep 11: 435-438 53. Marr KA, Bow E, Chiller T, Maschmeyer G, Ribaud P, Segal B, Steinbach W, Wingard JR,
Nucci M (2009): Fungal infection prevention after hematopoietic cell transplantation. Bone Marrow Transplant 44: 483-487 54. Kommission für Krankenhaushygiene und Infektionsprävention beim Robert-Koch-Institut (Exner M, Maschmeyer G, Christiansen B, Engelhart S, Hornei B, Wischnewski N, Simon
A) (2010): Anforderungen an die Hygiene bei der medizinischen Versorgung von
immunsupprimierten Patienten. Bundesgesundheitsbl 53: 357–388
55. Maschmeyer G (2011): Epidemiology of respiratory events in patients with hematological
malignancies. In: Azoulay E (Ed.): Pulmonary involvement in patients with hematological malignancies. Springer Verlag Berlin Heidelberg, S. 41-45 56. Maschmeyer G, Ljungman P (2011): Infections in patients undergoing hematopoietic stem
cell transplantation. In: Safdar A (Ed.): Management of Infections in Cancer Patients. Springer Verlag New York Heidelberg, S. 17-26 57. Maschmeyer G (2010): Infektionen bei immunkompromittierten Patienten. In: Van Aken,
Reinhart, Zimpfer, Welte (Hrsg.): Intensivmedizin. Georg Thieme Verlag Stuttgart (in Druck) 58. Maschmeyer G (2010): Invasive Pilzinfektionen. In: Van Aken, Reinhart, Zimpfer, Welte
(Hrsg.): Intensivmedizin. Georg Thieme Verlag Stuttgart (in Druck) 59. Maschmeyer G (2010): Aktuelle Richtlinien zur Antimykotika-Prophylaxe. In: Schmitt M
(Hrsg.): Antimykotische Prophylaxe bei Neutropenie und Immundefizienz. Uni-Med Verlag (in Druck) 60. Breywisch F (2011): Autologe hämatopoetische Stammzelltransplantation: Komplikationen.
In: Huber Ch et al (Hrsg.): Hämatopoetische Stammzellen: Grundlagen und Klinische Einsatzgebiete. 61. Maschmeyer G, Ruhnke M, Böhme A (2010): Diagnosis and management of fungal
infections in hematology and oncology. Hematology Education 4: 262-7 62. Maschmeyer G (2011): Invasive fungal disease: better survival through early diagnosis and
therapeutic intervention. Expert Rev Anti Infect Ther 9: 279-281 63. Sandherr M, Maschmeyer G (2011): Pharmacology and metabolism of voriconazole and
posaconazole in the treatment of invasive aspergillosis – review of the literature. Eur J Med Res 16: 139-44 64. Heußel CP, Bialek R, Arnold R, Deja M, Reinke P, Maschmeyer G (2011): Komplikationen
bei immuninkompetenten Patienten. Intensivmedizin und Notfallmedizin 48: 426-431 65. Müller-Löbnitz C, Eder M, Kluge S, Knitsch W, Kuse ER, Maschmeyer G, Quintel M, Welte
T (2011): Pulmonale Aspergillosen: Konsequenzen der neuen AGIHO-Empfehlungen für die klinische Praxis. Intensiv- und Notfallbehandlung, Jahrgang 37 - 1. Quartal (30 - 37) 66. Exner M, Engelhart S, Gebel J, Ilscher C, Pfeifer R, Höller C, Dilloo D, Maschmeyer G,
Simon A (2011): Hygiene-Tipps für immunsupprimierte Patienten zur Vermeidung übertragbarer Infektionskrankheiten. Hyg Med 36: 36-44 67. Maschmeyer G (2011): Invasive fungal disease: better survival through early diagnosis and
therapeutic intervention. Expert Rev Anti Infect Ther 9: 279-981 68. Maschmeyer G (2011): Diagnosis and antimicrobial therapy of lung infiltrates in febrile
neutropenic cancer patients. Curr Infect Dis Rep 13: 510-6 69. Maschmeyer G, Koch K, Jungehülsing M (2011): Kopf-Hals-Tumoren: Interdisziplinäre
Therapiekonzepte. Best Practice Onkologie 6: 4-20 70. Rothmann F, Maschmeyer G (2011): Die Bestimmung der freien Leichtketten (Freelite)
und der Immunglobulin-Kappa/Lambda-Subtypen (Hevylite) in der Diagnostik von Plasmazellerkrankungen. J Lab Med 35: 271-278 71. Peters U, Maschmeyer G (2011): Fieber und Infektionen. In: Aulbert/Nauck/Radbruch
(Hrsg.) Lehrbuch der Palliativmedizin, 3. Auflage. Schattauer Verlag Stuttgart, S. 410-418 72. Maschmeyer G (2011): Hygieneanforderungen in der Hämatologie und Onkologie: Die
neue RKI-Richtlinie. MedReview 18/2011: 6-7 73. Maschmeyer G (2012): Erkrankungen der Plasmazellen (NC Munshi, DL Longo, KC
Anderson). In: Dietel M, Suttorp N, Zeitz M (Hrsg.): Harrisons Innere Medizin, 18. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 1007-1015 74. Maschmeyer G (2012): Onkologische Notfälle (R Gucalp, J Dutcher). In: Dietel M, Suttorp
N, Zeitz M (Hrsg.): Harrisons Innere Medizin, 18. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 2450-2465 75. Maschmeyer G (2012): Spätfolgen von Krebserkrankungen und ihrer Behandlung (MC
Perry, DL Longo). In: Dietel M, Suttorp N, Zeitz M (Hrsg.): Harrisons Innere Medizin, 18. Auflage, McGraw-Hill, ABW Wissenschaftsverlag Berlin, S. 900-905
III. Publizierte Abstrakte

1. Maschmeyer G (2004): Gram-positive infections in cancer patients: the role of linezolid.
2. Büchner Th, Hiddemann W, Berdel WE, Wörmann B, Schoch C, Fonatsch C, Löffler H, Haferlach T, Ludwig WD, Maschmeyer G, Staib P, Balleisen L, Grüneisen A, Aul C,
Lengfelder E, Hehlmann R, Kern W, Serve HL, Mesters RM, Eimermacher H, Frickhofen N,
Kienast J, Giagounidis A, Sauerland MC, Heinecke A (2004): Subgroup specific therapy
effects in AML: AMLCG data. Ann Hematol 83 Suppl 1: S100-101
3. Maschmeyer G (2004): Management of febrile neutropenic patients with lung infiltrates. J
4. Cornely OA, Reuter S, Maertens J, Arenz D, Franz J, Ullmann AJ, Martino R, Böhme A, Cesaro S, Schiel X, Auner H, Chopra R, Gratwohl A, Jedrzejczak W, Karthaus M, Kiehl MG,
Krüger W, Maschmeyer G, Nosari A, Silling G (2004): Regimens and outcomes of current
approaches to secondary prophylaxis after proven or probable invasive fungal infections. A
multinational case registry. Clin Microbiol Infect 10 Suppl 3: 41
5. Cornely OA, Böhme A, Reuter S, Reichert D, Maschmeyer G, Silling G, Ullmann AJ,
Karthaus M, Wacker S, Wassmer G (2004): Efficancy of secondary antifungal prophylaxis and risk factors for breakthrough invasive fungal infection (IFI) after pulmonary IFI in AML patients – results from a multinational ccase registry. Onkologie 27 (Suppl 3): 9 6. Einsele H, Hebart H, Liebisch P, Bargou R, Meisner C, Metzner B, Wandt H, Wolf H, Sezer O, Casper J, Freund M, Pfreundschuh M, Dölken G, Maschmeyer G, Grimminger W,
Straka C, Trümper L, Kröger N, Hegewisch-Becker S, Müller P, Hertenstein B, Peest D,
Frickhofen N, Mitterer M, Coser P, Kanz L, Bensinger SWI (2004): Comparison of two high-
dose chemotherapy regomens and autologous stem cell transplantation in patients with de
novo multiple myeloma. Onkologie 27 (Suppl 3): 34
7. Cornely OA, Böhme A, Reuter S, Reichert D, Maschmeyer G, Silling G, Maertens J,
Ullmann AJ, Martino R, Karthaus M, Wacker S, Wassmer G (2004): Efficacy of secondary antifungal prophylaxis and risk factors for breakthrough infection after pulmonary IFI in AML patients: a multinational case registry. Abstract M-664, 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, October 2004, p. 410 8. Papp-Vary M, Oertel SHK, Maschmeyer G, Riess H (2004): Single dose per cycle
pegfilgrastim successfully supports full dose CHOP-21 in patients with post-transplant lymphoproliferative disorders (PTLD). Blood 104 (2): 232b 9. Einsele H, Liebisch P, Bargou R, Meisner Ch, Metzner B, Wandt H, Wolf HH, Sezer O, Casper J, Pfreundschuh M, Maschmeyer G, Straka Ch, Truemper L, Kroeger N, Mueller P,
Hertenstein B, Frickhofen N, Coser P, Bamberg M, Hebart H, Kanz L (2004): Single high-
dose chemoradiotherapy versus tandem high dose melphalan followed by auto-SCT for
advanced multiple myeloma. Preliminary analysis. Blood 104 (1): 156a
10. Kern W, Serve H, Staib P, Kerschgens Ch, Matylis A, Tischmann K, Huber Ch, Hirschmann WD, Eimermacher H, Lange JG, Zumsprekel A, Maschmeyer G, Unterhalt M, Ohnesorge
J, Sauerland MC, Berdel W, Büchner Th, Haferlach T, Schoch C, Ludwig WD, Hiddemann
W (2004): Prognostic impact of cytogenetics and early response and efficacy of sequential
high-dose araC and idarubicin (S-HAI) in patients with refractory and relapsed acute
myeloid leukemia (AML): Results of a prospective study. Blood 104 (1): 248a-249a
11. Einsele H, Liebisch P, Bargou R, Meisner Ch, Metzner B, Wandt H, Wolf HH, Sezer O, Casper J, Freund M, Pfreundschuh M, Doelken G, Maschmeyer G, Grimminger W, Straka
C, Truemper L, Kroeger N, Hegewisch-Becker S, Müller R, Hertenstein B, Peest N,
Frickhofen N, Mitterer M, Coser P, Hebart H, Bensinger W (2005): Intensified conditioning
therapy followed by a single auto-PBSCT versus tandem high-dose melphalan: preliminary
analysis. Bone Marrow Transplant 35 Suppl 2: S48
12. Maschmeyer G (2005): State of the art: antifungal therapy in cancer patients. Mycoses 48
13. Cornely OA, Maschmeyer G, Cesaro S, Arenz D, Effelsberg J, Eimermacher H, Haas A,
Maertens J, Martino R (2005): Secondary prophylaxis after invasive fungal infection of the central nervous system or retinitis. Mycoses 48 Suppl 2: 57 14. Cornely OA, Reichert D, Böhme A, Silling G, Reuter S, Martino R, Cesaro S, Maschmeyer
G, Buchheidt D, Maertens J, Gratwohl A, Kiehl M, Effelsberg J, Chopra R, Novo A, Penack
O, Eimermacher H, Haas A, Heinz W, Jedrzejcak W, Schiel X, Südhoff T (2005):
Voriconazole as secondary prophylaxis after invasive fungal infection. Onkologie 28 Suppl
3: 108
15. Haas A, Pasold R, Hierholzer J, Maschmeyer G (2005): Cure of cerebral aspergillosis in
AML folloed by intensive radiochemotherapy and autologous stem cell support – case report. Onkologie 28 Suppl 3: 108 16. Gerhardt A, Sogalla C, Lobeck H, Fleige B, Stein H, Maschmeyer G (2005): Excess
leukocytosis resulting from undifferentiated hepatic cancer. Onkologie 28 Suppl 3: 162 17. Bohlius J, Böhme A, Penack O, Engert A, Cornely OA, Maschmeyer G (2005):
Management of infections with hematopoietic growth factors. Onkologie 28 Suppl 3: 257 18. Maschmeyer G (2006): Defining clinical failure for salvage studies. Proceedings of 2nd
Advances Against Aspergillosis, Athens, February 22-25, 2006, S. 37 19. Strohscheer I, Bachmann F, Maschmeyer G, Samonigg H (2006): Retrospektive
Auswertung des Einsatzes von Antibiotika auf der Palliativstation. Palliativmedizin 7: S102 20. Gökbuget N, Arnold R, Böhme A, Bartram C, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig W, Maschmeyer G, Messerer D, Rieder H, Thiel E, Hoelzer D (2006):
Outcome of adult patients with relapsed acute T-lymphoblastic leukemia. Onkologie 29
(Suppl 3): 7
21. Maschmeyer G (2007): Update on the epidemiology of infections in cancer patients. Clin
22. Maschmeyer G (2007): Fungal infections in critically ill ICU patients. Infection 35 Suppl II:
23. Maschmeyer G (2007): How helpful are diagnostic techniques today? Onkologie 30 Suppl
24. Gökbuget N, Arnold R, Böhme A, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig W, Maschmeyer G, Messerer D, Rieder H, Thiel E, Hoelzer D for the German Multicenter
Study Group dor Adult ALL (GMALL) (2007): Improved outcome in high-risk and very high-
risk ALL treated according to the GMALL protocol 07/2003. Onkologie 30 Suppl 3: 44
25. Haas A, Maschmeyer G (2007): How can professional work of oncologists become more
efficacious in times of increased competition between hospitals? Onkologie 30 Suppl 3: 169 26. Gerhardt A, Sogalla C, Lobeck H, Horny HP, Feller AC, Sotlar K, Arnold R, Maschmeyer
G (2007): Systemic mastocytosis associated with clonal haematologic non-mast cell-lineage
disease after successful chemotherapy of AML with translocation t(8;21). Onkologie 30
Suppl 3: 221
27. Maschmeyer G (2007): New immunosuppressive agents as risk factors for fungal
infections. J Chemother 19 Suppl 3: 29 (abstr M3) 28. Gökbuget N, Arnold R, Böhme A, Bartram C, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig W, Maschmeyer G, Messerer D, Rieder H, Thiel E, Hoelzer D (2007):
Outcome of adult patients with relapsed acute T-lymphoblastic leukemia can be improved
with sequential salvage therapies and SCT in second CR. Haematologica 92 (Suppl 2): 10
29. Gökbuget N, Arnold R, Böhme A, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig WD, Maschmeyer G, Messerer D, Rieder H, Thiel E, Hoelzer D (2007): Improved outcome
in high-risk and very high-risk ALL by risk adapted SCT and in standard risk ALL by
intensive chemotherapy in 713 adult ALL patients treated according to the prospective
GMALL study 07/2003. Blood 110:11a (abstr 12)
30. Knop S, Bauer K, Hebart H, Wandt H, Trümper L, Liebisch P, Maschmeyer G, Peest D,
Wolf HH, Kröger N, Straka C, Pfreundschuh M, Coser P, Meisner C, Kanz L, Einsele H (2007): A randomized comparison of total-marrow irradiation, busulfan and cyclophosphamide with tandem high-dose melphalan in patients with multiple myeloma. Blood 110:223a (abstr 728) 31. Vehreschild J, Sieniawski M, Reuter S, Reichert D, Maertens J, Böhme A, Silling G, Martino R, Maschmeyer G, Ullmann A, Cornely O (2008): Efficacy of caspofungin compared to
itraconazole as secondary antifungal prophylaxis: a multinational case registry. Bone
Marrow Transplant;41Suppl1:S285
32. Maschmeyer G (2008): Fungal infections after transplantation. Int J Med Microbiol
33. Krüger WH, Schüler F, Niederwieser D, Basara N, Sayer H, Maschmeyer G, Haas A,
Kiefer T, Neumann T, Dölken G (2008): Treatment of mantle cell lymphoma by allogeneic stem cell transplantation – a preliminary report from the trial #060 and #074 of the East German Study Group for Hematology and Oncology (OSHO). Onkologie 31Suppl2:27 34. Vehreschild J, Sieniawski M, Reuter S, Reichert D, Maertens J, Böhme A, Silling G, Martino R, Maschmeyer G, Rüping MJGT, Ullmann AJ, Cornely OA (2008): Efficacy of caspofungin
compared to itraconazole as secondary antifungal prophylaxis: a multinational case registry.
Onkologie 31Suppl2:29
35. Maschmeyer G, Fritz L, Böhme A, Penack O, Schwerdtfeger R, Buchheidt D, Ludwig WD,
Neuburger S (2008): Well-fitting masks for prevention of invasive aspergillosis in high-risk neutropenic patients. Onkologie 31Suppl2:229 36. Maschmeyer G, Fritz L, Neuburger S, Böhme A, Penack O, Schwerdtfeger R, Buchheidt
D, Ludwig W (2008): Well-fitting masks for prevention of invasive aspergillosis in high-risk neutropenic patients. 48th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and 46th Infectious Diseases Society of America (IDSA) Annual Conference, Washington DC (USA), October 25-28, 2008, abstract #K-4101 37. Büchner T, Berdel WE, Haferlach C, Schnittger S, Haferlach T, Serve H, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Mesters R, Volpert S, Staib P, Grüneisen A, Kern W,
Reichle A, Ludwig WD, Maschmeyer G, Balleisen L, Eimermacher H, Aul C, Giagounidis A,
Rasche H, Hehlmann R, Lengfelder E, Koepcke W, Krug UO, Sauerland MC, Heinecke A,
Woermann BJ, Hiddemann W (2008): Older age is an independent risk factor in AML.
Abstracts of the 50th Annual Meeting of the American Society of Hematology, #555; Blood 112Suppl: 207 38. Becker C, Krahl R, Schulze A, Maschmeyer G, Junghanß C, Franke A, Peter N, Haenel M,
Wedding U, Wolf HH, Haehling D, Meran J, Doelken G, Kaempfe D, Kettner E, Grobe N, Florschuetz A, Kreibich U, Schirmer V, Ittel T, Schulze M, Huhn R, Zschuppe E, Opitz B, Assmann M, Hasenclever D, Poenisch W, Helbig W, Niederwieser DW (2008): Ten year follow up analysis of the OSHO phase III trial (AML 96) comparing different application modes of AraC in patients below 60 years with acute myeloid leukemia (AML): No impact of araC-application mode on remission rate, toxicity, disease-free survival or overall survival. Abstracts of the 50th Annual Meeting of the American Society of Hematology, #2966; Blood 112 Suppl: 1019 39. Krüger W, Basara N, Schüler F, Niederwieser D, Behre G, Grobe N, Sayer H, Maschmeyer
G, Haas A, Kiefer T, Neumann T, Dölken G (2009): Treatment of mantle cell lymphoma by
allogeneic stem cell transplantation – a preliminary report from the trials #060 and #074 of
the East German Study Group for Haematology and Oncology (OSHO). Abstracts of the
14th Congress of the European Hematology Association, Berlin 4-7 June, 2010,
Haematologica 94s2:291 (abstract #714)
40. Rüping MJGT, Heinz WJ, Kindo AJ, Rickerts V, Lass-Flörl C, Beisel C, Herbrecht R, Silling G, Roth Y, Ullmann AJ, Borchert K, Egerer G, Maertens J, Maschmeyer G, Simon A,
Wattad M, Fischer G, Vehreschild JJ, Cornely OA (2009): Forty-one cases of invasive
zygomycosis from a global clinical registry. Mycoses 52 Suppl1: 22;abstr #O2.3
41. Krüger W, Basara N, Hirt C, Niederwieser D, Behre G, Grobe N, Sayer H, Maschmeyer G,
Haas A, Kiefer T, Neumann T, Dölken G (2009): Treatment of mantle cell lymphoma by
allogeneic stem cell transplantation – a report from the ongoing trials #060 and #074 of the
East German Study Group for Haematology and Oncology (OSHO). Onkologie 32(suppl
4):30 (abstr #P147)
42. Jäkel N, Junghanss C, Maschmeyer G, Krahl R, Hoppe G, Eisfeld AK, Lange T,
Niederwieser D, Al-Ali HK (2009): Azacitidine in newly-diagnosed and refractory/relapsed AML not eligible for or resistant to chemotherapy: a multi-center phase I/II-study of the East German Haematology and Oncology Study Group (OSHO). Onkologie 32(suppl 4):113 (abstr #P430) 43. Knop S, Liebisch P, Kropff M, Wandt H, Mügge LO, Kröger N, Engelhardt M, Jung W, Wolf HH, Metzner B, Ostermann H, Hart C, Hertenstein B, Kaufmann M, Gramatzki M, Dölken G,
Rösler W, Schmitz N, Pfreundschuh M, Fischer T, Heidemann E, Hess G, Gollasch H,
Maschmeyer G, Weisel K, Bentz M, Kahl C, Dechow T, Brugger W, Jäger E, Kiani A,
Salwender H, Sezer O, Simon JP, Straka C, Fingerle-Rawson G, Einsele H (2009):
Bortezomib, iv cyclophosphamide and dexamethasone as induction therapy in newly
diagnosed multiple myeloma: update on the interim results with 300 patients of the German
DSMM XIa trial. Onkologie 32(suppl 4):82 (abstr #V333)
44. Rüping MJ, Vehreschild JJ, Heinz W, Rickerts V, Lass-Flörl C, Groll AH, Ullmann A, Maertens J, Herbrecht R, Kindo A, Roth Y, Wattad M, Egerer G, Maschmeyer G, Simon A,
Borchert K, Cornely OA (2009): Under the Fungiscope: 41 patients with invasive
zygomycosis. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy,
abstract #M-1049
45. Maschmeyer G (2009): Prophylaxis, empirical, preemptive therapy in presumed
aspergillosis in hematological patients: Which strategy? Mycoses 52 Suppl1: 5-6;abstr #W05.1 46. Maschmeyer G (2009): How one manages IMIs in the setting of continuous immune
suppression. Abstracts of the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA), #87 47. Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Bargou RC, Metzner B, Peest D, Aulitzky WE, Wandt H, Sezer O, Hentrich M, Ostermann H, Peschel C, Hess G, Hertenstein
B, Freund M, Kropff MH, Wolf HH, Jung W, Frickhofen N, Maschmeyer G, Mergenthaler
HG, Heidemann E, Kröger N, Straka C, Engel C, Kanz L, Meisner C, Einsele H (2009):
Allogeneic stem cell transplant versus tandem high-dose melphalan for front-line treatment
of deletion 13q14 myeloma – an interim analysis of the German DSMM V trial. Abstracts of
the 51st Annual Meeting of the American Society of Hematology, #51; Blood 2009;114:27
48. Einsele H, Liebisch P, Langer C, Kropff M, Wandt H, Jung W, Kröger N, Engelhardt M, Ostermann H, Mügge LO, Wolf HH, Hart C, Metzner B, Kaufmann M, Gramatzki M,
Hertenstein B, Fischer T, Weisel K, Dölken G, Brugger W, Gollasch H, Maschmeyer G,
Pfreundschuh M, Schmitz N, Sezer O, Heidemann E, Jäger E, Kahl C, Kiani A, Dechow T,
Rösler W, Simon JP, Dürk H, Pflüger KH, Bentz M, Hess G, Mergenthaler HG, Straka C,
Hempel D, Salwender HJ, Fingerle-Rowson G, Knop S (2009): Velcade, intravenous
cyclophosphamide and dexamethasone (VCD) induction for previously untreated multiple
myeloma (German DSMM XIa Trial). Abstracts of the 51st Annual Meeting of the American
Society of Hematology, #131; Blood 2009;114:59
49. Büchner T, Berdel WE, Haferlach C, Schnittger S, Haferlach T, Serve H, Müller-Tidow C, Braess J, Spiekermann K, Kienast J, Mesters R, Volpert S, Staib P, Grüneisen A, Kern W,
Reichle A, Ludwig WD, Maschmeyer G, Balleisen L, Eimermacher H, Aul C, Giagounidis A,
Rasche H, Hehlmann R, Lengfelder E, Köpcke W, Krug UO, Sauerland MC, Heinecke A,
Woermann BJ, Hiddemann W (2009): Long-term results in patients with acute myeloid
leukemia (AML): the influence of high-dose AraC, G-CSF priming, autologous
transplantation, prolonged maintenance, age, history, cytogenetics, and mutation status.
Data of the AMLCG 1999 Trial. Abstracts of the 51st Annual Meeting of the American
Society of Hematology, #485; Blood 2009;114:200
50. Rummel MJ, Niederle N, Maschmeyer G, Banat A, von Gruenhagen U, Losem C, Heil G,
Welslau M, Balser C, Kaiser U, Ballo H, Weidmann E, Duerk HA, Kofahl-Krause D, Roller F, Barth J, Hoelzer D, Hinke A, Brugger W (2009): Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Abstracts of the 51st Annual Meeting of the American Society of Hematology, # 405; Blood 2009;114:168 51. Zohren F, Bruns I, Barth J, Pechtel S, Fenk R, Schroeder T, Czibere AG, Maschmeyer G,
Kofahl-Krause D, Heil G, Niederle N, Losem C, Welslau M, Germing U, Kronenwett R, Haas R, Rummel MJ, Kobbe G (2009): Quantitative real-time PCR of peripheral blood t(14;18) positive cells predicts treatment response and long-term outcome in patients with follicular lymphoma. Abstracts of the 51st Annual Meeting of the American Society of Hematology, # 441, Blood 2009;114:183 52. Goekbuget N, Brueggemann M, Arnold R, Bartram CR, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig WD, Maschmeyer G, Messerer D, Raff T, Rieder H, Thiel E
Hoelzer D (2009): New definition of treatment response in adult acute lymphoblastic
leukemia (ALL): use of molecular markers for minimal residual disease (MRD). Abstracts of
the 51st Annual Meeting of the American Society of Hematology, # 90, Blood 2009;114:42
53. Schueler F, Basara N, Maschmeyer G, Fischer T, Herold M, Sayer HG, Wolf HH, Kreibich
U, Haehling D, Doelken G, Junghanss C, Grobe N, Krahl R, Al-Ali HK, Poenisch W, Niederwieser D (2009): Reduction of relapse incidence and improvement of leukemia free survival by allogeneic stem cell transplantation in patients with AML and normal karyotype irrespective of the FLT3-ITD status. Abstracts of the 51st Annual Meeting of the American Society of Hematology, # 1612, Blood 2009;114:644 54. Cross M, Jaekel N, Krahl R, Junghanss C, Maschmeyer G, Tran T, Hoppe G, Niederwieser
D, Al-Ali HK (2009): Low levels of global (LINE) and CDH13 methylation at diagnosis and rapid clearance of marrow blasts correlate with a better haematological response to azacitidine in patients with newly diagnosed and refractory/relapsed AML not eligible for or resistant to chemotherapy: A Multi-Centre Phase I/II-Study of the East German Haematology and Oncology Study Group (OSHO). Abstracts of the 51st Annual Meeting of the American Society of Hematology, # 2642, Blood 2009;114:1036-7 55. Burchardt CA, Brugger W, Maschmeyer G, Kofahl-Krause D, Fischer L, Roller F, Barth J,
Rummel MJ (2009): Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III study of B-R vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study Group Indolent Lymphomas, Germany). Abstracts of the 51st Annual Meeting of the American Society of Hematology, # 2679, Blood 2009;114:1048-9 56. Schüler F, Maschmeyer G, Fischer T, Herold M, Sayer HG, Wolf HH, Kreibich U, Hähling
D, Dölken G, Junghanss C, Grobe N, Krahl R, Lange T, Al-Ali HK, Basara N, Pönisch W, Niederwieser D for the East German Study Group Hematology and Oncology (OSHO) (2010): Allogeneic stem cell transplantation reduces the relapse incidence in patients with AML and normal karyotype independently of the FLT3-ITD status. Abstracts of the 36th Annual Meeting of the European Group for Blood and Marrow Transplantation, Wien, 21.-24.3.2010; #O-234 57. Herold M, Maschmeyer G, Lakner V, Dölken G, Ehninger G, Hänel M, Rohrberg R,
Hochhaus A, Neubauer A, Fischer L, von Grünhagen U, Hahnfeld S, Hoffmann F, Wußling M, Stein W, Kettner E, Hähling D (2010): Sustained survival advantage after a median follow-up of 5 years for immunochemotherapy (R-MCP) versus chemotherapy alone (MCP) in advanced follicular lymphoma – update of the OSHO#39 trial. Abstracts of the 15th Congress of the European Hematology Association, Barcelona, June 10-13, 2010, Haematologica 95s2:239 (abstr. #0575) 58. Niederwieser D, Schueler F, Hegenbart U, Maschmeyer G, Fischer T, Junghanss C, Wolf
H, Sayer HG, Kreibich U, Dölken G (2010): Improvement of leukemia-free survival and reduction of relapse incidence by allogeneic stem cell transplantation in elderly patients with AML irrespective of the FLT3-ITD and NPM status except NPM+FLT3-. Abstracts of the 46th Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, June 4-8, 2010, J Clin Oncol 28 (15S):489s, abstr #6509 59. Maschmeyer G, Heinz W, Hertenstein B, Horst HA, Requadt C, Wagner T, Ruhnke M
(2010): Immediate versus deferred antifungal treatment in high-risk patients with febrile neutropenia. Results from the randomized, double-blind, placebo-controlled, multicenter IDEA Study. 50th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Boston (USA), September 12-15, 2010, abstract #M-1061 60. Maschmeyer G (2010): "Fever of unknown origin" – mit Anamnese und Befund zur
Differentialdiagnose. Anästh Intensivmed 51:S694 61. Maschmeyer G (2010): What have we learned about systemic antifungals currently
available on the market? Abstracts of the 2nd Workshop of the European Confederation of Medical Mycology (ECMM), Milan 23-25 September 2010, p.64 62. Maschmeyer G (2010): Central venous catheter-associated infections. Onkologie
63. Herold M, Maschmeyer G, Lakner V, Dölken G, Ehninger G, Hänel M, Rohrberg R,
Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO) (2010): Survival advantage for immunochemotherapy (R-MCP) over chemotherapy (MCP) alone in advanced follicular lymphoma after a median follow up of 5 years – updated results of the OSHO#39 study. Onkologie 2010;33(suppl 6):132 64. Zohren F, Bruns I, Barth J, Pechtel S, Fenk R, Schroeder T, Maschmeyer G, Kofahl-
Krause D, Niederle N, Heil G, Losem C, Welslau M, Germing U, Kronenwett R, Rummel MJ, Haas R, Kobbe G (2010): Quantitative real-time PCR of circulating bcl2/IgH+ cells at diagnosis, after therapy and during follow-up predicts long-term outcome and imminent relapse in patients with follicular lymphoma. Onkologie 2010; 33(suppl 6):158 65. Gökbuget N, Brüggemann M, Arnold R, Bartram CR, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig WD, Maschmeyer G, Messerer D, Raff T, Rieder H, Serve H,
Thiel E, Hoelzer D (2010): Definition of molecular remission in adult acute lymphoblastic
leukemia based on minimal residual disease. Onkologie 2010; 33(suppl 6):213
66. Rummel MJ, Tenzer A, Niederle N, Losem C, Balser C, Balló HE, Welslau M, Grünhagen U, Brugger W, Maschmeyer G, Matzdorff AC, Ganser A, Weidmann E, Heil G, Hinke A, Barth
J (2010): No elevated rates of treatment-related myelodysplastic syndromes and second
solid tumors following therapy with bendamustine compared with other anti-lymphoma
regimes for low-grade Non-Hodgkin’s lymphoma. Abstracts of 52nd Annual Meeting of the
American Society of Hematology, Orlando FL, December 4-7, 2010, abstr #3090
67. Maschmeyer G (2011): Is it time to switch from empirical to preemptive treatment of IFI?
68. Niederwieser D, Maschmeyer G, Fischer T, Uharek L, Kortmann R, Hegenbart U, Dreger
P, Herold M, Sayer HG, Wolf H, Kreibich U, Hähling D, Junghanss C, Grobe N, Krahl R, Lange T, Al-Ali HK, Pönisch W, Nehring C, Doelken G (2011) Relapse incidence and leukemia-free survival (LFS) in patients (pts) older than age 60 with AML undergoing stem cell transplantation: A report of the East German Study Group Hematology and Oncology (OSHO). Abstracts of the 47th Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, June 3-7, 2011, J Clin Oncol 29 (suppl), abstr #6523 69. Lange T, Niederwieser D, Hoffmann V, Pfirrmann M, Maschmeyer G, Fischer T, Herold M,
Sayer HG, Junghanss C, Krahl R, Al-Ali HK, Pönisch W, Vucinic V, Doelken G, Sauerland MC, Heinecke A, Hoelzer D, Hehlmann R, Berdel WE, Büchner T (2011): Intergroup study in elderly patients with AML to compare complete remission rate and overall survival after intermediate-dose or low-dose AraC. Abstracts of the 47th Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, June 3-7, 2011, J Clin Oncol 29 (suppl), abstr #6618 70. Reinwald M, Spiess B, Heinz W, Vehreschild JJ, Lass-Flörl C, Kiehl M, Schultheis B, Krause SW, Wolf HH, Maschmeyer G, Hofmann WK, Buchheidt D (2011): Diagnosing
Pulmonary Aspergillosis in Patients with Hematologic Malignancies: Prospective evaluation
of an aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage
samples. 51st Annual Interscience Conference of Antimicrobial Agents and Chemotherapy
(ICAAC), Chicago (USA), September 17-20, 2011, abstract #M-486
71. Vehreschild MJ, Meissner A, Cornely OA, Maschmeyer G, Neumann S, v Lilienfeld-Toal M,
Karthaus M, Wattad M, Staib, Hellmich M, Christ H, Vehreschild JJ (2011): A clinical definition for chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. 51st Annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Chicago (USA), September 17-20, 2011, abstract #K-1124 72. Krüger WH, Basara N, Hirt C, Niederwieser D, Behre G, Grobe N, Sayer H, Maschmeyer
G, Haas A, Fischer T, Kiehl M, Busemann C, Dölken G (2011): Treatment of mantle cell
lymphoma by allogeneic stem cell transplantation – Results from the prospective trials #060 and #74 of the East German Study Group for Hematology and Oncology (OSHO). Onkologie 2011;34(suppl 6):70-71 73. Rothmann F, Rohland A, Maschmeyer G (2011): Clinical usefulness of the Hevylite assay
in patients with monoclonal gammopathy. Onkologie 2011;34(suppl 6): 157-158 74. Gökbuget N, Stanze D, Arnold R, Fietkau R, Freund M, Ganser A, Kneba M, Lipp T, Ludwig WD, Maschmeyer G, Messerer D, Rieder H, Thiel E, Serve H, Hoelzer D, German
Multicenter Study Group for Adult ALL (GMALL) (2011): Treatment of relapsed acute
lymphoblastic leukemia (ALL): improved results in GMALL studies but optimisation is an
ongoing challenge. Onkologie 2011;34(suppl 6): 17
75. Knop S, Liebisch P, Hebart H, Holler E, Engelhardt M, Bargou RC, Metzner B, Dölken G, Peest D, Aulitzky W, Bunjes D, Straka C, Wandt H, Sezer O, Hentrich M, Ostermann H,
Dechow T, Heß G, Hertenstein B, Freund M, Kropff M, Wolf H, Jung W, Frickhofen N,
Maschmeyer G, Mergenthaler H, Kanz L, Meisner C, Einsele H, Deutsche Studiengruppe
Multiples Myelom (DSMM) (2011): Up front allogeneic stem cell transplant is superior to
tandem high-dose melphalan in cytogenetically defined ultra high-risk myeloma. Onkologie
2011;34(suppl 6): 199-200
76. Reinwald M, Spiess B, Heinz W, Vehreschild JJ, Lass-Flörl C, Kiehl M, Schultheis B, Krause SW, Wolf HH, Maschmeyer G, Hofmann WK, Buchheidt D (2011): Prospective
multicenter evaluation of an aspergillus PCR assay and a galactomannan ELISA in
bronchoalveolar lavage samples of patients with hematologic malignancies for diagnosing
pulmonary aspergillosis. Onkologie 2011;34(suppl 6): 255
77. Vehreschild M, Meissner A, Cornely O, Maschmeyer G, Neumann S, v Lilienfeld-Toal M,
Karthaus M, Wattad M, Staib, Vehreschild JJ (2011): A clinical definition for early neutropenic enterocolitis predicts death. Onkologie 2011;34(suppl 6):302-303 78. Niederwieser D, Verdonck LF, Cornelissen JJ, Cross M, Krahl R, Lange T, Vucinic V, Franke G, Al-Ali HK, Ossenkoppele G, Maschmeyer G, Doelken G, Freund M, Peter N,
Boogaerts M, Gratwohl A, Schouten HC, Löwenberg B (2011): Long term outcome after low
dose TBI based conditioning hematopoietic stem cell transplantation from related and
unrelated donors for older patients with AML. Abstracts of 53rd Annual Meeting of the
American Society of Hematology, San Diego CA, December 10-13, 2011, abstr #2030
79. Goekbuget N, Stanze D, Arnold R, Brueggemann M, Fietkau R, Freund M, Ganser A, Ludwig WD, Maschmeyer G, Raff T, Rieder H, Thiel E, Serve H, Kneba M, Hoelzer D
(2011): Overall outcome of relapsed acute lymphoblastic leukemia can be improved by
stem cell transplantation and early treatment in stage of molecular relapse. Abstracts of
53rd Annual Meeting of the American Society of Hematology, San Diego CA, December 10-
13, 2011, abstr #250
80. Krüger WH, Hirt C, Basara N, Niederwieser D, Behre G, Grobe N, Sayer HG, Maschmeyer
G, Fischer T, Kiehl M, Busemann C, Doelken G (2011): Allogeneic stem cell transplantation
of mantle cell lymphoma – results of the prospective trials OSHO #060 and OSHO #074.
Abstracts of 53rd Annual Meeting of the American Society of Hematology, San Diego CA,
December 10-13, 2011, abstr #2014
81. Rummel MJ, Niederle N, Maschmeyer G, Banat AG, von Gruenhagen U, Losem C, Kofahl-
Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Duerk HA, Ballo H, Stauch M, Barth J, Hinke A, Brugger W, Study Group Indolent Lymphomas (StiL) (2012): Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): Updated results from the StiL NHL1 study. Abstracts of the 48th Annual Meeting of American Society of Clinical Oncology (ASCO), Chicago, June 1-5, 2012, J Clin Oncol 30, 2012 (suppl; abstr 3) 82. Schenk T, Maschmeyer G, Sayer HG, Kentouche K, Pletz M, Janka G, Lehmberg K,
Hochhaus A, La Rosée P (2012): Adults with hemophagocytic lymphohistiocytosis (HLH): an underestimated diagnosis? Initiative for an adult HLH registry. Onkologie 35 (suppl 6): 22 (abstr #V86) 83. Maschmeyer G (2012): Pulmonary complications in hematologic patients: fungal infections.
Onkologie 35 (suppl 6): 39 (abstr #V140) 84. Knödler M, Dietz A, Gauler T, Stoehlmacher J, Grünwald V, Rethwisch V, Frickhofen N, Haxel B, Schroeder M, Knipping S, Maschmeyer G, Guntinas-Lichius O, Keilholz U (2012):
An analysis of toxicity in patients with recurrent and/or metastatic squamous cell carcinoma
oft he head and neck receiving cetuximab, fluorouracil and cisplatin alone or with docetaxel
in a phase II clinical trial (CeFCiD). Onkologie 35 (suppl 6): 153 (abstr #P514)
85. Reiser M, Hensel M, Hoesl M, Janssen J, Jentsch-Ullrich K, Koenigsmann M, Lück A, Schwarzer A, Tschechne B, Hechenbichler K, Kellershohn K, Maschmeyer G (2012): Non-
interventional study of rituximab in the treatment of chronic lymphocytic leukemia (CCL
NIS): first interim results. Onkologie 35 (suppl 6): 217 (abstr #P723)
86. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-
Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk HA, Ballo H, Strauch MB, Roller F, Barth J, Hinke A, Burchardt AC, Brugger W (2012): Subanalysis oft he StiL NHL 1-2003 study: achievement of complete response with bendamustine-rituximab and CHOP-R in the first-line treatment of indolent and mantle cell lymphomas results in superior survival compared to partial response. Abstracts of 54th Annual Meeting of the American Society of Hematology, Atlanta GA, December 8-11, 2012, abstr #2724 87. Schenk T, Maschmeyer G, Rothmann F, Weber T, Christopeit M, Penack O, Goy D,
Panse J, Janka G, Hochhaus A, La Rosée P (2012): Adult patients with hemophagycytic lymphohistiocytosis (HLH) in Germany: a retrospective multicenter case study of 20 patients. Abstracts of 54th Annual Meeting of the American Society of Hematology, Atlanta GA, December 8-11, 2012, abstr #3271 88. Niederwieser D, Hoffmann VS, Krahl R, Berdel WE, Sauerland MC, Hiddemann W, Hegenbart U, Wörmann BJ, Krug U, Pönisch W, Vucinic V, Hebenstreit K, Cross M,
Niederwieser C, Pfirrmann M, Schulze A, Krämer A, Maschmeyer G, Freund M, Scholl S,
Heinicke T, Hähling D, Wolf HH, Büchner T (2012): Factors influencing complete remission
rate in patients ≥ 60 years with acute myeloid leukemia (AML): report from the German AML
Intergroup study. Abstracts of 54th Annual Meeting of the American Society of Hematology,
Atlanta GA, December 8-11, 2012, abstr #128
89. Maschmeyer G (2013): Lungenkarzinome. Pharmazeutische Zeizung 2013, S. 18-19
90. Knoedler M, Dietz A, Gauler TG, Gruenwald V, Stoehlmacher J, Knipping S, Guntinas- Lichius O, Frickhofen N, Schroeder M, Maschmeyer G, Rethwisch V, Haxel B, Keilholz U
(2013): Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in
patients with recurrent and/or metastatic squamous cell carcinoma oft he head and neck:
Interim results of a randomized phase II clinical trial (CeFCID). J Clin Oncol 31 (suppl): #
e17021

Source: http://www.klinikumevb.de/fileadmin/pflege/klinikum/HaemaOnko/130716_Publikationen_EvB.pdf

Microsoft word - cv - chamara senaratna - for usj website - 16.04.2012.doc

Dr. Chamara Senaratna MBBS, MSc, MD __________________________________________________________________ Department of Community Medicine, Faculty of Medical Sciences, Telephone: chamaravs@yahoo.com / chamaravs@sjp.ac.lk OVERVIEW • Senior Lecturer in Community Medicine, Faculty of Medical Sciences, University of Sri • Board-certified specialist in Community Medicine • V

Microsoft word - 50rev01en-dec-08.doc

IATA Dangerous Goods Regulations ADDENDUM Users of the IATA Dangerous Goods Regulations are asked to note the following amendments and corrections to the 50th Edition, effective from 1 January 2009. Where appropriate, changes or amendments to existing text have been highlighted (in yellow - PDF or grey - hardcopy) to help identify the change or amendment. New or Amended State Variations

Copyright © 2010-2014 Internet pdf articles